Virus cocktail takes on tough lung bugs in CF trial

NCT ID NCT07275905

First seen Jan 11, 2026 · Last updated May 05, 2026 · Updated 24 times

Summary

This early-stage trial tests whether a mixture of natural viruses called AchromoPhage is safe for adults with cystic fibrosis who have long-term lung infections from Achromobacter bacteria. Twelve participants will receive the treatment by inhalation, IV, or both, and be monitored for side effects over 42 days. The goal is to see if this approach can control the infection without causing serious harm.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS (CF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of California San Diego (UCSD)

    San Diego, California, 92037, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Pittsburgh

    Pittsburgh, Pennsylvania, 15213, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.